Elevai Labs Inc. executed a 1-for-200 reverse stock split on November 27, 2024, as per the Certificate of Amendment filed on November 20, 2024. The split, initially approved by the Board of Directors on July 23, 2024, and subsequently by stockholders on August 12, 2024, was finalized with the ratio set by the CEO on November 20, 2024.The reverse split had no effect on the par value of the Common Stock. Stockholders entitled to fractional shares received one whole share instead. The Common Stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 27, 2024, retaining the "ELAB" trading symbol but with a new CUSIP number (28622K 203).The company has adjusted the number of shares available for future grants under its equity incentive plan, as well as the number, exercise price, and terms of outstanding awards to reflect the effects of the split.

Elevai Labs Inc. executed a 1-for-200 reverse stock split on November 27, 2024, as per the Certificate of Amendment filed on November 20, 2024. The split, initially approved by the Board of Directors on July 23, 2024, and subsequently by stockholders on August 12, 2024, was finalized with the ratio set by the CEO on November 20, 2024.The reverse split had no effect on the par value of the Common Stock. Stockholders entitled to fractional shares received one whole share instead. The Common Stock began trading on a split-adjusted basis on The Nasdaq Capital Market on November 27, 2024, retaining the "ELAB" trading symbol but with a new CUSIP number (28622K 203).The company has adjusted the number of shares available for future grants under its equity incentive plan, as well as the number, exercise price, and terms of outstanding awards to reflect the effects of the split.